Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

21. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India

Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India 1 Evans V, et al. BMJ Glob Health 2018;3:e000263. doi:10.1136/bmjgh-2016-000263 Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India Valerie Evans, 1,2 Peter Roderick, 3 Allyson M Pollock 3 Analysis To cite: Evans V, Roderick P , Pollock AM. Adequacy of clinical trial evidence of metformin fixed (...) pharmaceutical landscape. Although metformin is a first-line treatment, FDCs for diabetes in India account for two-thirds of all diabetes medicine sales, and some have not been approved by the Central Drugs Standard Control Organization (CDSCO). This study examines the basis of efficacy and safety of top-selling metformin FDCs in India against four WHO criteria from clinical trials guidelines for the approval of FDCs. Data from a commercial drug sales database (PharmaTrac) were combined with searches through

BMJ global health2018 Full Text: Link to full Text with Trip Pro

22. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial 29483185 2018 02 27 1935-5548 2018 Feb 26 Diabetes care Diabetes Care Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial. dc171114 10.2337/dc17-1114 In patients with uncontrolled (...) type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart four or fewer times per day. Glycated hemoglobin (HbA 1c ) decreased from 8.2% (66 mmol/mol) to 6.7% (50 mmol/mol

EvidenceUpdates2018

23. Ertugliflozin - Steglatro, Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) - Type 2 diabetes

Ertugliflozin - Steglatro, Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) - Type 2 diabetes Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) Tablets U.S. Department of Health and Human Services Search FDA Submit search Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) Tablets Steglatro Company

FDA - Drug Approval Package2018

24. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial 29266675 2018 02 07 1463-1326 2017 Dec 21 Diabetes, obesity & metabolism Diabetes Obes Metab Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. 10.1111/dom (...) .13194 To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin. In this study (Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (HbA1c) ≥7.5% and ≤11.0% (≥58 and ≤97 mmol/mol) with metformin ≥1500 mg/d (n = 1233) were randomized to ertugliflozin 5 (E5) or 15 (E15) mg/d, sitagliptin 100 mg/d (S100) or to co-administration of E5/S100 or E15/S100

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

25. [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V]

[Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V] Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17 [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17 [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according (...) to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17. [Saxagliptin/metformin

Health Technology Assessment (HTA) Database.2018

26. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial 29227571 2018 01 23 1463-1326 2017 Dec 11 Diabetes, obesity & metabolism Diabetes Obes Metab Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients (...) : Analysis of results from the CONSENT trial. 10.1111/dom.13190 Metformin treatment for type 2 diabetes mellitus (T2DM) can be limited by gastrointestinal (GI) adverse events (AEs), resulting in treatment discontinuation. We investigated whether once-daily metformin extended release (XR) is superior in terms of GI tolerability, with non-inferior efficacy, compared with thrice-daily metformin immediate release (IR) in treatment-naïve Chinese patients with T2DM. This prospective, open-label, randomized

EvidenceUpdates2018

27. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial

Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial 29144061 2017 12 21 1463-1326 2017 Nov 16 Diabetes, obesity & metabolism Diabetes Obes Metab Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind (...) , placebo-controlled trial. 10.1111/dom.13161 This prospective, multicentre, phase III study (NCT02104804) evaluated the efficacy and safety of saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin ± metformin. Patients with glycated haemoglobin (HbA1c) 7.5% to 10.5% and fasting plasma glucose (FPG) <15 mmol/L (270 mg/dL) on stable insulin therapy (20-150 U/d) were randomized (1:1) to saxagliptin 5 mg once daily (N = 232) or placebo (N = 230) for 24 weeks

EvidenceUpdates2018

28. Metformin hydrochloride (Glucophage) - Reduction in the risk or delay of the onset of type 2 diabetes mellitus

Metformin hydrochloride (Glucophage) - Reduction in the risk or delay of the onset of type 2 diabetes mellitus Published 15 January 2018 Statement of Advice: metformin hydrochloride 500mg, 750mg and 1000mg prolonged release tablets (Glucophage SR ® ) SMC No 1308/18 Merck Serono Ltd 8 December 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation metformin hydrochloride (Glucophage SR ® ) is not recommended for use within NHS Scotland. Indication under review

Scottish Medicines Consortium2018

29. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome

Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome Electronic Physician(ISSN: 2008-5842) http://www.ephysician.ir December 2017, Volume: 9, Issue: 12, Pages: 5969-5973, DOI: http://dx.doi.org/10.19082/5969 Corresponding author: Kosar Hosseini Almadani, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran. Tel: +98.9122532998, Fax: +98.55545057, Email: k.hosseini145663@gmail.com Received: January 21, 2016, Accepted (...) : August 01, 2016, Published: December 2017 iThenticate screening: June 15, 2016, English editing: November 10, 2017, Quality control: November 12, 2017 © 2017 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial- NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Page 5969 Effect of metformin on the anti

Electronic physician2017 Full Text: Link to full Text with Trip Pro

30. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. BACKGROUND: Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia occurs secondary to insulin resistance and is associated with increased risk of cardiovascular disease and diabetes mellitus. Insulin-sensitising agents (...) such as metformin may be effective in treating PCOS-related anovulation. OBJECTIVES: To evaluate the effectiveness and safety of insulin-sensitising drugs in improving reproductive and metabolic outcomes for women with PCOS undergoing ovulation induction. SEARCH METHODS: We searched the following databases from inception to January 2017: Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL. We searched registers of ongoing trials and reference lists from

Cochrane2017

31. Health benefits of late-onset metformin treatment every other week in mice

Health benefits of late-onset metformin treatment every other week in mice ARTICLE OPEN Health bene?ts of late-onset metformin treatment every other week in mice Irene Alfaras 1 , Sarah J. Mitchell 1 , Hector Mora 1 , Darisbeth Rosario Lugo 1 , Alessandra Warren 2 , Ignacio Navas-Enamorado 1 , Vickie Hoffmann 3 , Christopher Hine 4 , James R. Mitchell 4 , David G. Le Couteur 2,5 , Victoria C. Cogger 2,5 , Michel Bernier 1 and Rafael de Cabo 1 Chronic 1% metformin treatment is nephrotoxic (...) in mice, but this dose may nonetheless confer health bene?ts if given intermittently rather than continuously. Here, we examined the effects of 1% metformin given every-other week (EOW) or two consecutive weeks per month (2WM) on survival of 2-year-old male mice fed standard chow. EOW and 2WM mice had comparable lifespancomparedwithcontrolmice.Asigni?cantreductioninbodyweightwithinthe?rstfewweeksofmetformintreatmentwas observed without impact on food consumption and energy expenditure. Moreover

NPJ aging and mechanisms of disease2017 Full Text: Link to full Text with Trip Pro

32. Peri-operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial

Peri-operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial 28940961 2017 09 23 2017 10 13 1463-1326 2017 Sep 20 Diabetes, obesity & metabolism Diabetes Obes Metab Peri-operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial. 10.1111/dom.13118 Historically, metformin was withheld before surgery for fear of metformin-associated lactic (...) acidosis. Currently, however, this risk is deemed to be low and guidelines have moved towards the continuation of metformin. We hypothesized that continuing metformin peri-operatively would lower postoperative serum glucose level without an effect on plasma lactate levels. We performed a single-blind multicentre randomized controlled trial in people with type 2 diabetes mellitus scheduled for non-cardiac surgery and continued (MF+ group) or withheld (MF- group) metformin before surgery. The main

EvidenceUpdates2017

33. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial

Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial 28926170 2017 09 19 2017 10 26 1463-1326 2017 Sep 19 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study (...) , a multicentre, randomized, double-blind, active-controlled, phase 3 trial. 10.1111/dom.13117 To assess the efficacy and safety of saxagliptin plus metformin over 24 weeks in pharmacotherapy-naïve Chinese patients with type 2 diabetes mellitus and inadequate glycaemic control (HbA1c, 8.0%-12.0%). In this multicentre, double-blind, active-controlled study (The START study: NCT02273050, clinicaltrials.gov), patients were randomized (1:1:1) to saxagliptin 5 mg plus metformin, saxagliptin 5 mg plus placebo

EvidenceUpdates2017

34. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study 28921862 2017 09 18 2017 10 24 1463-1326 2017 Sep 17 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled (...) randomized study. 10.1111/dom.13116 To assess ertugliflozin in patients with type 2 diabetes who are inadequately controlled by metformin and sitagliptin. In this double-blind randomized study (Clinicaltrials.gov NCT02036515), patients (glycated haemoglobin [HbA1c] 7.0% to 10.5% [53-91 mmol/mol] receiving metformin ≥1500 mg/d and sitagliptin 100 mg/d; estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m(2) ) were randomized to ertugliflozin 5 mg once-daily, 15 mg once-daily or placebo

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

35. Metformin for endometrial hyperplasia.

Metformin for endometrial hyperplasia. BACKGROUND: Endometrial cancer is one of the most common gynaecological cancers in the world. Rates of endometrial cancer are rising, in part because of rising obesity rates. Endometrial hyperplasia is a precancerous condition in women that can lead to endometrial cancer if left untreated. Endometrial hyperplasia occurs more commonly than endometrial cancer. Progesterone tablets currently used to treat women with endometrial hyperplasia are associated (...) with adverse effects in up to 84% of women. The levonorgestrel intrauterine device (Mirena Coil, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA) may improve compliance, but it is invasive, is not acceptable to all women, and is associated with irregular vaginal bleeding in 82% of cases. Therefore, an alternative treatment for women with endometrial hyperplasia is needed. Metformin, a drug that is often used to treat people with diabetes, has been shown in some human studies to reverse

Cochrane2017

36. Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin

Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin 29225676 2018 11 13 1753-495X 10 4 2017 Dec Obstetric medicine Obstet Med Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. 170-173 10.1177/1753495X17725465 To examine whether the reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is mediated by changes in insulin resistance. This was a secondary (...) analysis of obese pregnant women in a randomised trial (MOP trial). Fasting plasma glucose and insulin were measured in 384 of the 400 women who participated in the MOP trial. Homeostasis model assessment of insulin resistance (HOMA-IR) was compared in the metformin and placebo groups and in those that developed preeclampsia versus those that did not develop preeclampsia. At 28 weeks, median HOMA-IR was significantly lower in the metformin group. Logistic regression analysis demonstrated

Obstetric medicine2017 Full Text: Link to full Text with Trip Pro

37. Metformin in patients with moderate renal impairment: reduce the dose

Metformin in patients with moderate renal impairment: reduce the dose Prescrire IN ENGLISH - Spotlight ''In the October issue of Prescrire International - Metformin in patients with moderate renal impairment: reduce the dose'', 1 October 2017 {1} {1} {1} | | > > > In the October issue of Prescrire International - Metformin in patients with moderate renal impairment: reduce the dose Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight In the October issue of Prescrire International - Metformin in patients with moderate renal impairment: reduce the dose FREE DOWNLOAD This month's sample page is taken from the Adverse Effects section. Metformin is the first-choice oral glucose-lowering drug in type 2 diabetes, but it can provoke lactic acidosis, a rare but sometimes fatal adverse effect. What does this mean for patients with moderate renal

Prescrire2017

38. Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naive patients with type 2 diabetes

Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naive patients with type 2 diabetes 28857388 2017 08 31 2017 10 02 1463-1326 2017 Aug 31 Diabetes, obesity & metabolism Diabetes Obes Metab Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. 10.1111/dom.13104 This international, randomized (...) , double-blind trial (NCT01864174) compared the efficacy and safety of metformin extended-release (XR) and immediate-release (IR) in patients with type 2 diabetes. After a 4-week placebo lead-in, pharmacotherapy-naïve adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once-daily metformin XR 2000 mg or twice-daily metformin IR 1000 mg for 24 weeks. The primary endpoint was change in HbA1c after 24 weeks. Secondary endpoints were change in fasting plasma glucose

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

39. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) 28857451 2017 08 31 2017 10 02 1463-1326 2017 Aug 31 Diabetes, obesity & metabolism Diabetes Obes Metab Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). 10.1111/dom.13103 We evaluated (...) the efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0%-10.5%) with metformin monotherapy (≥1500 mg/d for ≥8 weeks). This was a double-blind, 26-week, multicentre study with ongoing 78-week extension (ClinicalTrials.gov identifier: NCT02033889). A total of 621 participants were randomized 1:1:1 to placebo, or ertugliflozin 5 or 15 mg/d. The primary endpoint was change from baseline at week 26 in HbA1c. Secondary efficacy

EvidenceUpdates2017

40. Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial

Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial 28759403 2017 07 31 2017 08 31 2017 08 31 1098-4275 140 1 2017 Jul Pediatrics Pediatrics Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. e20164285 10.1542/peds.2016-4285 Metformin has shown its effectiveness in treating obesity in adults. However, little research has been conducted in children, with a lack of attention on pubertal status. The objectives were (...) to determine whether oral metformin treatment reduces BMI z score, cardiovascular risk, and inflammation biomarkers in children who are obese depending on pubertal stage and sex. This was a randomized, prospective, double-blind, placebo-controlled, multicenter trial, stratified according to pubertal stage and sex, conducted at 4 Spanish clinical hospitals. Eighty prepubertal and 80 pubertal nondiabetic children who were obese aged 7 to 14 years with a BMI >95th percentiles were recruited. The intervention

EvidenceUpdates2017